Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer

Breast Cancer Clinical Trial

— C-PiACs  

Official title:

Feasibility Study on the Characterization of the Immune Profile of Young Patients After Treatment for Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04645849
• Other study ID #: 38RC19.362
• Secondary ID: 2019-A02900-57
• Status: Recruiting
• Start date: June 15, 2020
• Est. completion date: November 2021

Study information

• Verified date: December 2020
• Source: University Hospital, Grenoble
• Contact: Leila Gofti-Laroche, PharmD
• Phone: 0033 4 76 76 68 74
• Email: LGofti-laroche[@]chu-grenoble.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aim to determine kinetic of post treatment recovery/variation of a panel of innate and adaptative immune system cells and molecules.

The results should allow to determine the optimal post treatment immunomonitoring timing and panel to be used for future studies.

Description:

There is a complexe interaction between tumor cells ans host immunity. Immunity system (IS) is clearly involved in cancer developement control, and it is suggested that it could participate to the response to anti cancer treatment.

There is however no validated immunomonitoring strategy to allow a reliable patient's immune status along time, and particularly after treatment.There are scarce existing information on immunologic reconstitution profile recovery after treatment.

This study aim to perform immunomonitoring in young patients with cancer to describe kinetic of recovery/variation of a panel of innate and adaptative immune system cells and molecules, selected by their potential relevance according to literature.

The concerned population are young women (˂40 yo) with breast cancer.

There will be 2 patients cohorts A or "End of treatment" : patients recruited at the end of treatment (study cohort) B or "Diagnosis" : Patients recruited at diagnosis (reference values)

This study should contribute to give sufficient data to determine the pertinent timing and cells/molecules panel to evaluate immunity profiling after treatment.

These results could be used for further studies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 26
• Est. completion date: November 2021
• Est. primary completion date: August 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 39 Years

Eligibility

Inclusion Criteria:

• Women with Breast cancer at initial diagnosis OR at the end of treatment

• Chemotherapy planned or performed in the treatment plan

• Patient not opposed to participate to the present study

• Affiliated to a French social security scheme.

Exclusion Criteria:

• metastatic breast cancer

• pregnant or breastfeeding woman

• Treatment with monoclonal antibodies or immunotherapy

• Immunosuppressive therapy

• Thymus irradiation

• Chronic infection in progress

• Inborn or acquired disease (other than breast cancer) impacting the immune system (SAA, Lupus…)

• Subject under guardianship or deprived of liberty

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Biological:
• Immunomonitoring
16 patients will be recruited at the end of treatment: an immunoprofiling analysis will be performed out of a blood sample about 1 month, 5 months and 9 months after treatment. 8 patients will be recruited at diagnosis: a immune profile analysis will be performed before the start of treatment. This will give comparative values for the immune system cells and molecules.

Locations

Country	Name	City	State
France	Chu Grenoble Alpes	Grenoble

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Grenoble

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of the relevant biological parameters of the innate / adaptive immune system	Analysis of immune profile implies to evaluate changes of about 30 distinct immune cell (sub)types with their activation markers. These analyses are conducted at 3 time points for cohort "A or End of treatment" (1, 5, 9 months) and once for cohort "B or Diagnosis" before treatment start : -% and counts of immune cell populations (B-lymphocytes, T-lymphocytes, dendritic cells); activation levels of cell subpopulations; Secretion of cytokines after activation; Determination of cytokines and chemokines after activation (picograms/ml) Description of the evolution of the parameters measured for cohort "A or End of treatment" with comparison to normal values (data from the EFS cohort and from cohort "B or Diagnosis") Analysis of the reconstitution kinetic should allow us to determine wich biological parameters (immune cell (sub)types and their activation markers) will be most relevant to study immune profile reconstitution for further studies.	15 months
Secondary	Analysis feasibility	number of samples analysed versus planned, quality of the results	15 months
Secondary	Immunity Cells and molecules kinetic analysis	The objective is to determine the best moment for analysis of immune system reconstitution (cf outcome 1 measures) For each patient, and each immune system marker tested (cells/molecules): kinetic analysis of return to values comparable to reference values (data from the EFS = french blood establishment and the 8 patients tested before the start of treatment).	15 months